KIM PETER S 4
4 · Entrada Therapeutics, Inc. · Filed Mar 21, 2024
Insider Transaction Report
Form 4
KIM PETER S
Director
Transactions
- Purchase
Common Stock
2024-03-21$13.24/sh+704$9,318→ 49,776 total - Purchase
Common Stock
2024-03-19$12.66/sh+900$11,397→ 47,944 total - Purchase
Common Stock
2024-03-20$12.66/sh+1,128$14,281→ 49,072 total
Footnotes (3)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.59 to $12.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.55 to $12.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.11 to $13.26, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.